News & Updates

CVD prevention better with ACE inhibitor–statin combo than monotherapy
CVD prevention better with ACE inhibitor–statin combo than monotherapy
08 Jul 2022

In patients with hypertension, combined treatment with angiotensin-converting enzyme (ACE) inhibitors plus statins reduces the risk of developing cardiovascular disease (CVD) at a greater magnitude as compared with ACE inhibitor monotherapy, a study has found.

CVD prevention better with ACE inhibitor–statin combo than monotherapy
08 Jul 2022
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
07 Jul 2022
Empagliflozin improves outcomes in HFpEF patients regardless of age
Empagliflozin improves outcomes in HFpEF patients regardless of age
06 Jul 2022 byStephen Padilla

Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.

Empagliflozin improves outcomes in HFpEF patients regardless of age
06 Jul 2022
Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
06 Jul 2022

One out of five severe COVID-19 survivors who underwent mechanical ventilation have coronary artery disease (CAD), a quarter have subclinical left ventricular dysfunction defined as reduced echocardiographic global longitudinal strain (GLS), and 42 percent have cardiac magnetic resonance (CMR) abnormalities, reports a study.

Cardiovascular events not uncommon in ICU-admitted COVID-19 survivors
06 Jul 2022